Burt’s Bees Nature-Based Sensitive Skin Care Clinical Results Published in Journal of Drugs in Dermatology

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180813005082/en/

Burt’s Bees Sensitive Skin (Photo: Business Wire)

Burt’s Bees’ nature-based regimen, consisting of Sensitive Facial Cleanser, Sensitive Daily Moisturizing Cream and Sensitive Night Cream, was shown to be well-tolerated, as well as clinically, and statistically, superior to the control, a leading dermatologist-recommended synthetic regimen.

“The data suggest that nature-based products can be effective for patients who seek alternatives to conventional, synthetic skin care products,” said Zoe Draelos, MD, Dermatology Consulting Services, High Point, NC, the study’s principal investigator. “Patients with sensitive skin saw a clinical improvement in overall skin appearance, specifically in visual and tactile smoothness, clarity, and radiance.”

This 4-week, double-blind, randomized study was conducted in 120 women with sensitive skin who suffer from clinically diagnosed rosacea, atopic dermatitis/eczema, or cosmetic intolerance. Results demonstrated that Burt’s Bees Sensitive Skin Regimen clinically and statistically improved physician-rated overall skin appearance by 34% with similar improvements in visual and tactile smoothness, clarity and radiance. In contrast, the maximum improvement in women using the synthetic regimen was 4%.

No clinically significant tolerability issues were reported in either regimen after 4 weeks of daily administration. Both regimens improved epidermal barrier function as measured by transepidermal water loss. The Burt’s Bees regimen optimized skin hydration to improve and maintain skin health. The synthetic regimen was associated with over hydration possibly resulting from the occlusive barrier it provides.

“These data support the efficacy of nature-based formulations on sensitive skin, as well as the benefit of homeostasis of the epidermal barrier for overall skin health, including maintaining appropriate levels of hydration and allowing skin to breathe,” said Hemali Gunt, PhD, Head of Clinical and Scientific Affairs, at Burt’s Bees. “This publication affirms the benefit of natural products for sensitive skin, and offers an effective option as more people seek natural alternatives to conventional formulas.”

Read the full-text article in the JDD August 2018 issue: http://jddonline.com/articles/dermatology/S1545961618P0908X/1

About the Study: A participant- and investigator –blinded, controlled product, single site study was performed in an outpatient setting on one hundred and twenty female subjects, 19-60 years old, with Fitzpatrick skin types I-V. All subjects were diagnosed with either: eczema/atopic dermatitis, rosacea, or cosmetic intolerance syndrome. The evaluation was performed at baseline, 2 and 4 weeks of twice daily randomized treatment with Burt’s Bees Skin Care Regimen or a leading conventional skin care brand regimen. The Burt’s Bees Skin Care Regimen included Burt’s Bees Sensitive Facial Cleanser (used day and night), Burt’s Bees Sensitive Daily Moisturizing Cream (used in the day) and Burt’s Bees Sensitive Night Cream (used at night). The Control Skin Care Regimen included a leading conventional brand Skin Cleanser (used day and night) and a leading conventional brand Moisturizing Lotion (used day and night).

The peer review article is entitled: “Evaluation of the Performance of a Nature-Based Sensitive Skin Regimen in Subjects with Clinically Diagnosed Sensitive Skin” [Draelos ZD, Levy SB, Lutario C, Gunt H. J Drugs Dermatol. 2018; 17(8): 611-616].

Burt’s Bees^® has been offering distinctive earth-friendly, natural health and beauty care products for over 30 years. From a beekeeper’s backyard in Maine to the leading edge of natural, Burt’s Bees knows natural solutions for beauty from the inside out and operates with The Greater Good™ top of mind. www.burtsbees.com NYSE: CLX CLX-B

View source version on businesswire.com: https://www.businesswire.com/news/home/20180813005082/en/